Yanan Ren

Yanan Ren

Auto-generated profile, based on publicly available information

Yanan Ren

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing) Department of Nuclear Medicine Peking University Cancer Hospital & Institute 100142 Beijing China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
XDXiaojiang Duan
Xiaojiang Duan
LXLei Xia
Lei Xia
ZZZhuochen Zhang
Zhuochen Zhang
YRYanan Ren
Yanan Ren
MPMartin Pomper
Martin Pomper
XYXing Yang
Xing Yang
Purpose: Nectin-4 is an emerging biomarker for cancer diagnosis and therapy. Recently, enfortumab vedotin (EV) was approved by the FDA as the first nectin-4 targeting antibody–drug conjugate for treating advanced urothelial carcinoma (UC). A PET imaging method to noninvasively quantify nectin-4 expression level would potentially help to select patients most likely to respond to EV and predict the response. Experimental Design: In this study, we designed a bicyclic peptide-based nectin-4 targeting radiotracer 68Ga-N188. Initially, we performed preclinical evaluations of 68Ga-N188 in UC cell lines and xenograft mouse models. Next, we performed the translational study in healthy volunteers and a pilot cohort of patients with advanced UC on uEXPLORER total-body PET/CT. Results: In the preclinical study, 68Ga-N188 showed high affinity to nectin-4, specific uptake in a nectin-4(+) xenograft mouse model, and suitable pharmacokinetic and safety profiles. In the translational study, 2 healthy volunteers and 14 patients with advanced UC were enrolled. The pharmacokinetic profile was determined for 68Ga-N188, and the nectin-4 relative expression level in different organs was quantitatively imaged. Conclusions: A clear correlation between PET SUV value and nectin-4 expression was observed, supporting the application of 68Ga-N188 PET as a companion diagnostic tool for optimizing treatments that target nectin-4. See related commentary by Jiang et al., p. 3259

9 May 2023
Verified
Other
Open access
XDXiaojiang Duan
Xiaojiang Duan
LXLei Xia
Lei Xia
ZZZhuochen Zhang
Zhuochen Zhang
YRYanan Ren
Yanan Ren
MPMartin Pomper
Martin Pomper
XYXing Yang
Xing Yang
Purpose:Nectin-4 is an emerging biomarker for cancer diagnosis and therapy. Recently, enfortumab vedotin (EV) was approved by the FDA as the first nectin-4 targeting antibody–drug conjugate for treating advanced urothelial carcinoma (UC). A PET imaging method to noninvasively quantify nectin-4 expression level would potentially help to select patients most likely to respond to EV and predict the response.Experimental Design:In this study, we designed a bicyclic peptide-based nectin-4 targeting radiotracer 68Ga-N188. Initially, we performed preclinical evaluations of 68Ga-N188 in UC cell lines and xenograft mouse models. Next, we performed the translational study in healthy volunteers and a pilot cohort of patients with advanced UC on uEXPLORER total-body PET/CT.Results:In the preclinical study, 68Ga-N188 showed high affinity to nectin-4, specific uptake in a nectin-4(+) xenograft mouse model, and suitable pharmacokinetic and safety profiles. In the translational study, 2 healthy volunteers and 14 patients with advanced UC were enrolled. The pharmacokinetic profile was determined for 68Ga-N188, and the nectin-4 relative expression level in different organs was quantitatively imaged.Conclusions:A clear correlation between PET SUV value and nectin-4 expression was observed, supporting the application of 68Ga-N188 PET as a companion diagnostic tool for optimizing treatments that target nectin-4.

9 May 2023
Verified
Other
Open access
PDF file
XDXiaojiang Duan
Xiaojiang Duan
LXLei Xia
Lei Xia
ZZZhuochen Zhang
Zhuochen Zhang
YRYanan Ren
Yanan Ren
MPMartin Pomper
Martin Pomper
XYXing Yang
Xing Yang
Quality control of 68Ga-N188 used in this study

9 May 2023
Verified
Other
Open access
PDF file
XDXiaojiang Duan
Xiaojiang Duan
LXLei Xia
Lei Xia
ZZZhuochen Zhang
Zhuochen Zhang
YRYanan Ren
Yanan Ren
MPMartin Pomper
Martin Pomper
XYXing Yang
Xing Yang
Information of healthy subjects and urothelial carcinoma patients enrolled in PET/CT imaging studies using 68Ga-N188 and 18F-FDG

9 May 2023
Verified
Other
Open access
XDXiaojiang Duan
Xiaojiang Duan
LXLei Xia
Lei Xia
ZZZhuochen Zhang
Zhuochen Zhang
YRYanan Ren
Yanan Ren
MPMartin Pomper
Martin Pomper
XYXing Yang
Xing Yang
40 min full dynamic Total-body PET imaging of Patient 8

9 May 2023
Verified
Other
Open access
XDXiaojiang Duan
Xiaojiang Duan
LXLei Xia
Lei Xia
ZZZhuochen Zhang
Zhuochen Zhang
YRYanan Ren
Yanan Ren
MPMartin Pomper
Martin Pomper
XYXing Yang
Xing Yang
40 min full dynamic Total-body PET imaging of Patient 6